Aminex Therapeutics Announces Multiple Sites Activated for Phase 1b/2 Clinical Trial of Novel Investigational Cancer Treatment AMXT 1501 and DFMO in Patients with Breast Cancer or Melanoma
PR Newswire —
Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system SEATTLE, Feb. 4, 2026 /PRNewswire/ -- Aminex Therapeutics, Inc., a private clinical-stage biotechnology company focused on developing novel therapies for rare and...